Cancer Research Technology and Teva Pharmaceutical Industries Limited Form R&D Alliance for Cancer DNA Damage Response Drugs
Published: Sep 16, 2013
JERUSALEM & LONDON--(BUSINESS WIRE)--Cancer Research Technology Ltd. (CRT), Cancer Research UK’s technology development arm, and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells.
Help employers find you! Check out all the jobs and post your resume.